Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

Shih Hsin Tu; Chih Chiang Chang; Ching Shyang Chen; Ka Wai Tam; Ying Jan Wang; Chia Hwa Lee; Hsiao Wei Lin; Tzu Chun Cheng; Ching Shui Huang; Jan Show Chu; Neng Yao Shih; Li Ching Chen; Sy Jye Leu; Yuan Soon Ho; Chih Hsiung Wu

doi:10.1007/s10549-009-0492-0

Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

Shih Hsin Tu, Chih Chiang Chang, Ching Shyang Chen, Ka Wai Tam, Ying Jan Wang, Chia Hwa Lee, Hsiao Wei Lin, Tzu Chun Cheng, Ching Shui Huang, Jan Show Chu, Neng Yao Shih, Li Ching Chen, Sy Jye Leu, Yuan Soon Ho, Chih Hsiung Wu

Research output: Contribution to journal › Article › peer-review

108 Citations (Scopus)

Abstract

Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P

Original language	English
Pages (from-to)	539-553
Number of pages	15
Journal	Breast Cancer Research and Treatment
Volume	121
Issue number	3
DOIs	https://doi.org/10.1007/s10549-009-0492-0
Publication status	Published - Jun 2010

Keywords

Breast cancer
Enolase-1
Estrogen receptor alpha
Nuclear factor kappa B
Tamoxifen

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-009-0492-0

Cite this

Tu, S. H., Chang, C. C., Chen, C. S., Tam, K. W., Wang, Y. J., Lee, C. H., Lin, H. W., Cheng, T. C., Huang, C. S., Chu, J. S., Shih, N. Y., Chen, L. C., Leu, S. J., Ho, Y. S., & Wu, C. H. (2010). Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Research and Treatment, 121(3), 539-553. https://doi.org/10.1007/s10549-009-0492-0

Tu, SH, Chang, CC, Chen, CS, Tam, KW, Wang, YJ, Lee, CH, Lin, HW, Cheng, TC, Huang, CS, Chu, JS, Shih, NY, Chen, LC, Leu, SJ, Ho, YS & Wu, CH 2010, 'Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells', Breast Cancer Research and Treatment, vol. 121, no. 3, pp. 539-553. https://doi.org/10.1007/s10549-009-0492-0

@article{a0a9c9dcd0874f329c963e3821bedbf7,

title = "Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells",

abstract = "Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P ",

keywords = "Breast cancer, Enolase-1, Estrogen receptor alpha, Nuclear factor kappa B, Tamoxifen",

author = "Tu, {Shih Hsin} and Chang, {Chih Chiang} and Chen, {Ching Shyang} and Tam, {Ka Wai} and Wang, {Ying Jan} and Lee, {Chia Hwa} and Lin, {Hsiao Wei} and Cheng, {Tzu Chun} and Huang, {Ching Shui} and Chu, {Jan Show} and Shih, {Neng Yao} and Chen, {Li Ching} and Leu, {Sy Jye} and Ho, {Yuan Soon} and Wu, {Chih Hsiung}",

note = "Funding Information: Acknowledgments This study was supported by the National Science Council, grant NSC 95-2320-B-038-016-MY3 for Dr. Ho, and NSC 96-2314-B-038-002 for Dr. Wu, and by the Cathay Medical Center (95CGH-TMU-09 and 96CGH-TMU-05).",

year = "2010",

month = jun,

doi = "10.1007/s10549-009-0492-0",

language = "English",

volume = "121",

pages = "539--553",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

AU - Tu, Shih Hsin

AU - Chang, Chih Chiang

AU - Chen, Ching Shyang

AU - Tam, Ka Wai

AU - Wang, Ying Jan

AU - Lee, Chia Hwa

AU - Lin, Hsiao Wei

AU - Cheng, Tzu Chun

AU - Huang, Ching Shui

AU - Chu, Jan Show

AU - Shih, Neng Yao

AU - Chen, Li Ching

AU - Leu, Sy Jye

AU - Ho, Yuan Soon

AU - Wu, Chih Hsiung

N1 - Funding Information: Acknowledgments This study was supported by the National Science Council, grant NSC 95-2320-B-038-016-MY3 for Dr. Ho, and NSC 96-2314-B-038-002 for Dr. Wu, and by the Cathay Medical Center (95CGH-TMU-09 and 96CGH-TMU-05).

PY - 2010/6

Y1 - 2010/6

N2 - Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P

AB - Enolase-α (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (≤1 year, *P

KW - Breast cancer

KW - Enolase-1

KW - Estrogen receptor alpha

KW - Nuclear factor kappa B

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=77953122846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953122846&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0492-0

DO - 10.1007/s10549-009-0492-0

M3 - Article

C2 - 19655245

AN - SCOPUS:77953122846

SN - 0167-6806

VL - 121

SP - 539

EP - 553

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -

Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this